Anti-vascular endothelial growth factor (anti-VEGF) treatment is considered an adjuvant to ablative treatment for Coats disease and can facilitate the resolution of subretinal fluid and exudation and control disease progression (21–23). Here, VEGFA is linked to Coats disease.